Literature DB >> 24515988

Changes in fundus autofluorescence after treatments for polypoidal choroidal vasculopathy.

Tetsuya Yamagishi1, Hideki Koizumi1, Taizo Yamazaki1, Shigeru Kinoshita1.   

Abstract

BACKGROUND/AIMS: To evaluate changes in fundus autofluorescence (FAF) after treatments for polypoidal choroidal vasculopathy (PCV).
METHODS: Thirty-six eyes of 35 patients with treatment-naive PCV underwent intravitreal injection of ranibizumab, photodynamic therapy, or a combination of both treatments. FAF and indocyanine green angiography (ICGA) at baseline were compared with those obtained 12 months later about the changes at the affected lesion.
RESULTS: In the 36 eyes, 88 polyps were detected on ICGA at baseline, and 65 (73.9%) of those showed centred hypoautofluorescence and a circumferential hyperautofluorescent ring on FAF. Twelve months later, ICGA revealed resolution of 42 of those 65 polyps. Of those 42 resolved polyps, 30 hyperautofluorescent rings (71.4%) were eliminated concurrently with the resolution of polyp. Statistical analysis revealed that an elimination of the hyperautofluorescent ring was more frequently observed in association with the resolved polyps than with the persistent polyps (p<0.0001). All the hypoautofluorescent findings corresponding to branching vascular networks at baseline were unchanged during the follow-up period.
CONCLUSIONS: Elimination of the hyperautofluorescent ring is highly associated with the resolution of the polyp on ICGA. We propose that FAF has a potential as a non-invasive method of evaluating the therapeutic efficacy of treatments for PCV. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24515988     DOI: 10.1136/bjophthalmol-2013-303739

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  Characteristic appearances of fundus autofluorescence in treatment-naive and active polypoidal choroidal vasculopathy: a retrospective study of 170 patients.

Authors:  Xinyu Zhao; Song Xia; Youxin Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-04-14       Impact factor: 3.117

Review 2.  Polypoidal Choroidal Vasculopathy in Asians.

Authors:  Chee Wai Wong; Tien Y Wong; Chui Ming Gemmy Cheung
Journal:  J Clin Med       Date:  2015-04-24       Impact factor: 4.241

3.  Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.

Authors:  Yong Cheng; Xuan Shi; Jin-Feng Qu; Ming-Wei Zhao; Xiao-Xin Li
Journal:  Chin Med J (Engl)       Date:  2016-11-05       Impact factor: 2.628

4.  Characteristics of Fundus Autofluorescence in Active Polypoidal Choroidal Vasculopathy.

Authors:  Zafer Öztaş; Jale Menteş; Serhad Nalçacı; Mine Barış
Journal:  Turk J Ophthalmol       Date:  2016-08-15

5.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21

6.  Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy.

Authors:  Taiichi Hikichi; Hirokuni Kitamei; Shoko Shioya
Journal:  BMC Ophthalmol       Date:  2016-05-16       Impact factor: 2.209

7.  Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.

Authors:  Gregg T Kokame; James C Lai; Raymond Wee; Ryan Yanagihara; Jessica G Shantha; Julia Ayabe; Kelsi Hirai
Journal:  BMC Ophthalmol       Date:  2016-07-27       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.